《新股表現》高視醫療(02407.HK)首日掛牌低開0.4%
內地眼科醫療器械商高視醫療(02407.HK)首日掛牌,開市報51.2元,較上市價51.4元低0.4%,最新報48.5元,低上市價5.6%。
高視是次來港上市發售1,306.86萬股,並引入「無錫視高、無錫高視與中德基金」及CLKiwi兩名基石投資者,兩者共認購630.44萬股;其中10%公開發售獲0.52倍超購,集資淨額料約2.83億元,主要用作改善公司研發能力和加速其專利商業化、提高產能及增強製造能力,以及償還公司計息借款等。上市聯席保薦人分別大摩及海通國際。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.